Table 2.

Outcomes of the patients in protocol MT103-211

Primary efficacy endpoint
CR + CRh* n (%; 95% CI)77 (42%; 34%–49%)
Key supporting analyses
 CR n (%; 95% CI)60 (32%; 26%–40%)
 Median RFS for CR (range)6.7 months (0.5–16.5 mo)
Key exploratory analysis
 MRD-negative CR + CRh* n (%; 95% CI)58 (31%; 25%–39%)

Abbreviations: CRh*, CR but with platelets > 50 Gi/L and ANC > 0.5 Gi/L; MRD, (negative is <10−4); RFS, relapse-free survival (used as a measure of duration of response).